Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA-4783 + Paclitaxel in Metastatic Melanoma
NCT00084214Phase 2Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elesclomol in melanoma (2 arms), sponsored by Synta Pharmaceuticals Corp. Primary endpoint: Tumor Response. Started May 2004; status: completed.
02
Drugs
elesclomol
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00084214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084214.